We are live on ! Find out more

Femasys

FEMY

Market cap $12.6M

1.50 USD

-0.06

3.85%

At close Updated Oct 23, 4:00 PM EDT

1 day

-3.85%

5 days

-13.29%

1 month

-41.86%

3 months

-60.42%

6 months

-81.18%

Year to date

-88.22%

1 year

-87.67%

5 years

-98.93%

10 years

-99.38%

About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Employees: 54

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 81.8%

Negative 0%

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- -- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.

Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. FEMY's $30M PIPE recapitalization ties full funding to commercial traction; current market cap is below cash, creating a deep value setup. The investment thesis hinges on commercial execution: a lean, focused sales force converting OB/GYNs and health systems to the Fertility FastTrack suite.

Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo, taking place October 24–28 at the Baltimore Convention Center in Baltimore, Maryland. The Company will highlight FemaSeed® Intratubal Insemination (ITI), a first-step fertility treatment option, together with FemVue®, its complementary diagnostic solution for in-office fallopian tube evaluation at booth #513.

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care

-- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women's Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions.

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations. “We launched our OB/GYN commercial initiative at the ACOG Annual Clinical & Scientific Meeting on May 1st with the goal of bringing fertility evaluation and treatment earlier in the care pathway, and we are thrilled that a leading academic health system such as UNC Health is making these important technologies available within its OB/GYN practices,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys.

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology.

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company's non-surgical permanent birth control technology. These patents broaden and extend FemBloc's global intellectual property protection, complementing existing patents covering its delivery system and further strengthening the technology's competitive position in a highly regulated market with rigorous clinical and regulatory requirements.

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

See News Rankings

Price charts implemented using Lightweight Charts™